Overview
LUNG FUNG GROUP (2290)
Lung Fung Group Holdings Limited, through its subsidiaries, sells beauty, health and pharmaceutical products. The company offers Chinese and western medicines,...
- Open
- 3.790
- High
- 3.895
- Low
- 3.700
- Prev. Close
- 3.705
- Volume
- 2.08M
- Turnover
- 8.01M
- Avg Price
- 3.843
- Bid/Ask Ratio
- -43.28%
- Amplitude
- 5.26%
- 52wk High
- 4.700
- Volume Ratio
- 0.69
- Turnover Ratio
- 0.42%
- 52wk Low
- 2.010
- HK Mkt Cap
- 1.95B
- Market CapHKD
- 1.95B
- P/ETTM
- 7.23
- P/EDynamic
- 7.23
- P/EStatic
- --
- EPSTTM
- 0.538
- EPSDynamic
- 0.538
- EPSStatic
- --
- BVPS
- 0.09
- P/B
- 42.17
- HK Shares
- 500.00M
- Dividend YieldTTM
- 3,933.16%
- DividendTTM
- 153
- Shares
- 500.00M
- Min lot size
- 500
- Currency
- HKD
LUNG FUNG GROUP Analyst Rating
View moreForecast & Rating
Sep 30, 2026- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 0
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Lung Fung Group Holdings rose about 5.0% to HK$3.890 from a prior close of HK$3.705, tracing a one-way advance from the 09:30 session low of HK$3.705 to an intraday peak of HK$3.895 at 15:53, as store expansion drove double-digit same-store sales growth and DBS projected 20% revenue growth for 1H FY2027 with a Buy rating. Q1 2026 revenue reached HK$697.4 million, up 42.48% year on year, net profit came in at HK$47.76 million, up 130.68%, and net margin widened to 6.85% from 4.23%, while the consensus target price was lifted 25.20% to HK$10.19. The stock is up 38.43% year to date, above its MA20 of HK$3.696 but still below MA60 of HK$3.993, and sits 17.23% below its 52-week high of HK$4.70, with PE at 7.23x and market value HK$1.945 billion. Volume remains thin, though, with the shares up only 2.07% earlier in the week and the turnover rate at 0.42%.
- Oct, 23
Lung Fung Group opened weak but climbed, dipping to HK$3.63 in the morning session before spiking to HK$3.885 in the afternoon and closing at HK$3.740, up about 0.9% from the prior close of HK$3.705 on roughly 1.8 million shares. The move was underpinned by fundamentals and sell-side expectations: Q1 2026 revenue reached HK$697.4 million, up 42.5% year-on-year, with net profit of HK$47.76 million up 130.7% and net margin widening to 6.85% from 4.23%; interim in-store retail sales were about HK$1.7195 billion, up 18.9%, with same-store growth of 10.2%, while DBS expects first-half revenue growth of about 20% and the consensus price target was raised 25.2% to HK$10.19. Though the shares still trade below the MA20 of HK$4.274 and MA60 of HK$3.981, about 20.4% under the 52-week high of HK$4.70, and are up 33.1% year-to-date.
- Oct, 21
Lung Fung Group (2290.HK) spiked and faded: it printed HK$4.055 at 09:39 BJ, slid to HK$3.730 by 10:33, then traded between HK$3.795 and HK$3.865 in the afternoon to close at HK$3.825, about 4.3% under the prior close of HK$3.995 on roughly HK$10.58m turnover. No matching new disclosure appeared, so the move reads more like profit-taking after the HK$4.70 52-week high of 8 October, leaving the shares 18.94% below that peak and under both the MA20 (HK$4.333) and MA60 (HK$3.976), while still up 35.59% year-to-date. Fundamentals point the other way: Q1 revenue of HK$697.4m and net profit of HK$47.8m rose 42.48% and 130.68% year-on-year, net margin widening from 4.23% to 6.85%, DBS expects roughly 20% H1 revenue growth and the consensus target was lifted 25.20% to HK$10.19. A counterpoint: the company also disclosed leasing new premises from chairman Tse Siu Hoi and renewing two leases.
- Oct, 16
Lung Fung Group (2290.HK) reversed intraday, opening at 4.405 HKD as the session high before sliding to 4.055 HKD at 14:44 BJ and settling at 4.170 HKD, roughly 5% below the open, on 1.503 million shares and a 0.30% turnover rate. The tape contrasted with firmer operating data: half-year same-store sales grew 10.2% with in-store retail sales of about 1.7195 billion HKD, up roughly 18.9% year on year, while Q1 2026 revenue reached 697.4 million HKD (+42.48%), net profit 47.76 million HKD (+130.68%) and net margin widened to 6.85% from 4.23%. At a 2.085 billion HKD market capitalisation the shares trade on 7.75x earnings and remain below the 10.19 HKD consensus target, which was raised 25.20% this week; DBS expects first-half revenue growth of 20%, and the company has leased a ground-floor shop on Canton Road in Tsim Sha Tsui for 800,000 HKD a month, though thin volume limits price elasticity.
- Oct, 15
Lung Fung Group Holdings reversed early gains, climbing to HK$4.495 in the morning before sliding to an intraday low of HK$4.265 in the afternoon session and closing at HK$4.270, down 5.3% from the previous close of HK$4.510. The pullback leaves the shares about 9.15% below the 52-week high of HK$4.70 set on 8 October, still up 51.96% year to date, while the close has slipped under the 20-day moving average of HK$4.384. Fundamentals run the other way: Q1 2026 revenue grew 42.48% year on year to HK$697.4 million and net profit rose 130.68% to HK$47.76 million. DBS expects first-half revenue growth of 20%, the consensus target was raised 25.20% from HK$8.14 to HK$10.19, and the company leased a ground-floor shop on Canton Road in Tsim Sha Tsui at HK$800,000 monthly rent. Turnover stays thin, though, at 0.26% with a 7.93x P/E.
News
Market Movers · Lung Fung Group climbs nearly 5%
Weekly Review · Weekly Recap | LUNG FUNG GROUP +2.07%, beating the Hang Seng Index by about 5 points
Weekly Review · Weekly Recap | LUNG FUNG GROUP +6.09%, consensus target above spot
Global Report · Hong Kong Small-Caps Pivot Amid Market Pressures: M&A, Repositioning and New Bets
Global Report · Nine Hong Kong Small Caps Filed at Once. The Income Statement Moved First
Weekly Review · Weekly Recap | LUNG FUNG GROUP -10.31%, muted volume
